Intel Corporation (NASDAQ: INTC) shares are trading down roughly 1% Friday afternoon at $37.75 after the stock gained Thursday despite broader weakness in semi stocks.
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.